Pendred’s syndrome |
SLC26A4
|
Endemic cretinism |
Environmental |
[34] |
Monogenic skeletal disorders (e.g., Holt–Oram syndrome, radius aplasia-thrombocytopenia syndrome) |
e.g., TBX5, RBM8A
|
Thalidomide embryopathy |
Environmental |
[34,38] |
North Carolina macular dystrophy (NCMD) grade 3 |
locus chr5p15-p13 |
Congenital toxoplasmosis |
Environmental |
[41] |
North Carolina macular dystrophy (NCMD) grade 1 |
DHS6S1
|
Foveal hypoplasia |
Unknown |
[41] |
North Carolina macular dystrophy (NCMD) grade 2 |
PROM1
|
Torpedo maculopathy |
Unknown |
[41] |
Hypertrophic cardiomyopathy |
Sarcomeric genes |
Glycogen storage diseases (e.g., Danon disease) |
Monogenic |
[42,43,44] |
|
|
Lisosomal storage diseases (e.g., Fabry disease) |
Monogenic |
|
|
|
Mitocondrial cytopathies (e.g., MELAS) |
Monogenic |
|
|
|
AL amyloidosis |
Unknown |
|
Autoimmune lymphoproliferative syndrome (ALPS) |
FAS, FASLG, CASP10
|
ALPS phenocopies |
Somatic mutations in FAS (non-Mendelian genetic mechanism) |
[47,48,49] |
Cryopyrinopathies |
NLRP3
|
Cryopyrinopathies phenocopies |
Somatic mutations in NLRP3 (non-Mendelian genetic mechanism) |
[47] |
Hereditary angioedema |
SERPING1
|
Acquired angioedema |
Autoantibodies anti-C1-inhibitor (complex mechanism) |
[50] |
Chronic mucocutaneous candidiasis |
Genes encoding IL-17, IL-22 |
Recurrent fungal infections |
Autoantibodies anti-IL17 or IL-22 (complex mechanism) |
[51] |
Familial Parkinson’s disease |
SNCA, LRRK2, PRKN, PINK1 and others |
Familial Parkinson’s disease negative for mutations in known genes |
Unknown |
[53,54] |
Familial breast cancer |
BRCA1, BRCA2
|
Familial breast cancer negative for mutations in BRCA genes |
Unknown (probably genetic) |
[56,57] |
Huntington disease (HD) |
HTT
|
HD phenocopies |
Monogenic (mutations in genes different from HTT) |
[58,59] |
Brugada syndrome |
SCN5A
|
Brugada phenocopies (e.g., metabolic abnormalities, ischemia, mechanic compression, myocardial and pericardial diseases) |
Unknown (probably complex) |
[60,61,62] |